Dermatology practical & conceptual · 2026
Interplay of Biological Treatment and Psychological Features in Patients with Psoriasis: A Real-Life Prospective Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moretta Gaia, Samela Tonia, Provini Alessia, Pagnanelli Gianluca, Graceffa Dario, Orsini Diego, Lora Viviana, Richetta Antonio Giovanni, Dattola Annunziata, Amato Simone, Bernardini Nicoletta, Tribuzi Paola, Zangrilli Arianna, Vultaggio Martina, Bianchi Luca, Caldarola Giacomo, De Luca Eleonora, De Simone Clara, Giordano Domenico, Masini Cinzia, Bavetta Mauro, Lechiancole Stefania, Panasiti Vincenzo, Abeni Damiano
Аннотация
INTRODUCTION: Emotional dysregulation (ED), common among patients with psoriasis, leads to psychopathology and impairs treatment adherence.
OBJECTIVE: This study examined the changes in prevalence of ED in patients and its effects on illness perception, mental health, and quality of life (QoL) during one year of treatment with risankizumab.
METHOD: ED, illness perception, general health, and QoL were measured at baseline, and at four, 16, and 52 weeks posttreatment in 58 patients with psoriasis.
RESULTS: Higher ED was associated with greater psychological distress and poorer QoL. Patients with higher levels of ED reported greater psychological distress, worse QoL, and higher symptom-related distress throughout treatment as compared to those with lower ones. Although both groups improved in terms of illness perception and clinical severity outcomes, patients with high ED consistently experienced worse subjective outcomes.
CONCLUSION: ED is frequent in psoriasis patients and negatively affects mental health and QoL, despite clinical improvements in skin symptoms. Targeted psychological interventions may be necessary for patients who exhibit higher levels of emotional dysregulation to ensure comprehensive care and better long-term outcomes.
OBJECTIVE: This study examined the changes in prevalence of ED in patients and its effects on illness perception, mental health, and quality of life (QoL) during one year of treatment with risankizumab.
METHOD: ED, illness perception, general health, and QoL were measured at baseline, and at four, 16, and 52 weeks posttreatment in 58 patients with psoriasis.
RESULTS: Higher ED was associated with greater psychological distress and poorer QoL. Patients with higher levels of ED reported greater psychological distress, worse QoL, and higher symptom-related distress throughout treatment as compared to those with lower ones. Although both groups improved in terms of illness perception and clinical severity outcomes, patients with high ED consistently experienced worse subjective outcomes.
CONCLUSION: ED is frequent in psoriasis patients and negatively affects mental health and QoL, despite clinical improvements in skin symptoms. Targeted psychological interventions may be necessary for patients who exhibit higher levels of emotional dysregulation to ensure comprehensive care and better long-term outcomes.